A randomised phase II study evaluating tumour response to Dual inhibition of EGFR signalling using CetUXimab and Erlotinib or dose escalated Cetuximab in patients with chemotherapy refractory KRAS wild-type metastatic colorectal cancer

Trial Profile

A randomised phase II study evaluating tumour response to Dual inhibition of EGFR signalling using CetUXimab and Erlotinib or dose escalated Cetuximab in patients with chemotherapy refractory KRAS wild-type metastatic colorectal cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Cetuximab; Doxycycline; Erlotinib; Hydrocortisone
  • Indications Colorectal cancer; Erythema
  • Focus Biomarker; Therapeutic Use
  • Acronyms DUX2
  • Most Recent Events

    • 18 Jul 2013 Status changed from not yet recruiting to discontinued as reported by Australian New Zealand Clinical Trials Registry.
    • 06 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top